IP Library Granted Patent US 10,143,655
Granted Patent B2
US 10,143,655 · App. 15/233,794 · Granted Dec 4, 2018

Method of drug formulation

Inventors: Mark Hokenson (Camarillo, CA); Keith A. Oberg (Valencia, CA)
Assignee: MannKind Corporation
A61K9/1676A61K9/0073A61K9/167A61K9/1611A61K9/1617A61K9/1623A61K9/5052A61K9/5089A61K38/13A61K38/22A61K38/25A61K38/26A61K38/27A61K38/28A61K38/29
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,143,655
App. No.
15/233,794
Granted
Dec 4, 2018
Kind
B2
Abstract

Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.

Claims (26)

1. A method for making a microparticle coated with an active agent, the method comprising:

i. combining (a) a microparticle comprising crystalline fumaryl diketopiperazine, (b) an active agent, and (c) a solvent for said active agent thereby forming a suspension of said microparticles with said active agent;

ii. adding an active agent modifier to said suspension wherein adding said active agent modifier causes adsorption of said active agent onto said microparticle.

2. The method of claim 1 , wherein said active agent modifier is a salt, surfactant, ion, osmolyte, alcohol, chaotrope, kosmotrope, acid, base, or anti-solvent.

3. The method of claim 1 further comprising removing said solvent subsequent to said adsorption of the active agent.

4. The method of claim 2 , wherein said anti-solvent is an aqueous solvent.

5. The method of claim 4 wherein said anti-solvent is an organic solvent.

6. The method of claim 2 , wherein said anti-solvent is an organic solvent.

7. The method of claim 6 wherein said anti-solvent is water.

8. The method of claim 2 , wherein said salt is sodium chloride.

9. The method of claim 2 , wherein said osmolyte is hexylene-glycol, trehalose, glycine, polyethylene glycol, trimethylamine N-oxide, mannitol, or proline.

10. The method of claim 2 , wherein said alcohol is methanol, ethanol, trifluoroethanol, or hexafluoroisopropanol.

11. The method of claim 2 , wherein said chaotrope is NaSCN, (CH 3 ) 3 N—HCl, Na 2 NO 3 , NaClO 4 , or CsCl.

12. The method of claim 2 , wherein said kosmotrope is sodium citrate or sodium sulfate.

13. The method of claim 1 , wherein at least 70% of said active agent becomes adsorbed to said microparticle.

14. The method of claim 1 , wherein at least 80% of said active agent becomes adsorbed to said microparticle.

15. The method of claim 1 , wherein at least 90% of said active agent becomes adsorbed to said microparticle.

16. The method of claim 1 , wherein all of said active agent becomes adsorbed to said microparticle.

17. The method of claim 1 , wherein said microparticle is coated with a monolayer of said active agent.

18. The method of claim 1 , wherein adding said active agent modifier favorably modulates one or more energetic interactions with said microparticle.

19. The method of claim 18 , wherein said one or more energetically favorable interactions between said active agent and said microparticle comprises a hydrophobic interaction.

20. The method of claim 18 , wherein said one or more energetically favorable interactions between said active agent and said microparticle comprises a hydrogen bonding interaction.

21. The method of claim 18 , wherein said one or more energetically favorable interactions between said active agent and said microparticle comprises an electrostatic interaction.

22. The method of claim 1 , wherein adding said active agent modifier modifies the structure, flexibility, rigidity, solubility or stability of said active agent.

23. The method of claim 1 , wherein said active agent is a peptide or a protein.

24. The method of claim 1 , wherein said active agent is an insulin and an insulin analog.

Assignments (5)
PATENT SECURITY AGREEMENT Recorded Aug 12, 2025
From: MANNKIND CORPORATION
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 072444/0525 →
RELEASE OF SECURITY INTEREST Recorded Apr 5, 2024
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: MANNKIND CORPORATION; MANNKIND LLC
Reel/Frame 067024/0082 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2019
From: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; HORIZON SANTE FLML SARL
To: MANNKIND CORPORATION
Reel/Frame 050044/0138 →
SECURITY INTEREST Recorded Aug 13, 2019
From: MANNKIND CORPORATION; MANNKIND LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050044/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2016
From: HOKENSON, MARK; OBERG, KEITH A.
To: MANNKIND CORPORATION
Reel/Frame 039469/0771 →
Continuity (6)
Continuation 14746656 · Jun 22, 2015
Division 12883369 · Sep 16, 2010
Continuation 11532065 · Sep 14, 2006
Provisional Application 60717524 · Sep 14, 2005
Provisional Application 60744882 · Apr 14, 2006
Related Publication 20160346212A1 · Dec 1, 2016